Valuation: Immuneering Corporation

Market Cap 265M 234M 221M 199M 377M 25.36B 381M 2.65B 1.02B 12.97B 994M 972M 41.65B P/E 2026 *
-3.66x
P/E 2027 * -3.26x
Enterprise Value 265M 234M 221M 199M 377M 25.36B 381M 2.65B 1.02B 12.97B 994M 972M 41.65B EV / Sales 2026 *
-
EV / Sales 2027 * 13.6x
Free-Float
86.18%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Immuneering Corporation

1 day-0.85%
1 week-11.17%
Current month-17.94%
1 month-17.94%
3 months-18.91%
6 months-17.44%
Current year-37.77%
1 week 4.06
Extreme 4.065
4.4
1 month 4.06
Extreme 4.065
5.1
Current year 3.86
Extreme 3.86
8.48
1 year 3.86
Extreme 3.86
8.48
3 years 1
Extreme 1
10.08
5 years 1
Extreme 1
31.88
10 years 1
Extreme 1
33.99
Manager TitleAgeSince
Chief Executive Officer 44 2008-01-31
Director of Finance/CFO 61 2026-07-15
Chief Tech/Sci/R&D Officer - 2023-07-31
Director TitleAgeSince
Chairman 81 2007-12-31
Director/Board Member 44 2008-01-31
Director/Board Member 72 2021-04-26
Date Insider Type Main position Quantity % Market Cap. Importance
7/16/26 Other

Chief Financial Officer

225,000 0.3478%
7/16/26 Free

Chief Financial Officer

650,000 1.0047%
3/13/26 Free

Head of Human Resources

3,628 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
-0.85%-11.17%-39.33%-46.68% 267M
+4.16%-0.30%+58.96%+94.17% 71.53B
-0.19%-1.01%+38.55%+83.85% 60.12B
-1.51%+2.20%+10.66%+35.15% 48.85B
-0.05%-0.46%+48.77%+36.65% 44.28B
+0.38%+6.43%+345.54%+641.55% 43.83B
+0.18%-0.58%+9.95%+103.45% 41.53B
-0.67%-0.45%+4.47%+46.37% 30.13B
+4.77%+6.46%+41.54%+22.78% 27.98B
-1.29%-5.53%-19.42%+352.04% 25.25B
Average +0.49%-0.61%+49.97%+136.93% 39.38B
Weighted average by Cap. +0.80%+0.62%+64.93%+148.42%

Financials

2026 *2027 *
Net sales - 19.5M 17.21M 16.29M 14.7M 27.76M 1.87B 28.07M 195M 75.04M 956M 73.21M 71.61M 3.07B
Net income -74.1M -65.4M -61.91M -55.86M -105M -7.1B -107M -742M -285M -3.63B -278M -272M -11.66B -85.92M -75.83M -71.78M -64.77M -122M -8.23B -124M -860M -331M -4.21B -323M -316M -13.52B
Net Debt - -
Logo Immuneering Corporation
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
Employees
57
Date Price Change Volume
26-09-30 US$4.090 -0.97% 596,819
26-09-29 US$4.130 -0.72% 574,595
26-09-28 US$4.160 -2.58% 598,654
26-09-25 US$4.270 -1.61% 513,539
26-09-24 US$4.340 -0.91% 590,128
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.090USD
Average target price
17.17USD
Spread / Average Target
+319.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMRX Stock